New drug aims to shrink hard-to-treat HER2 cancers in early trial
NCT ID NCT06714617
First seen Nov 05, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 changes (either too much HER2 protein or a HER2 gene mutation). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have already tried at least one standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hematology Oncology Associates of the Treasure Cost
Port Saint Lucie, Florida, 34952, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
SCRI-Denver HealthOne
Denver, Colorado, 37203, United States
-
SCRI-Florida Cancer Center Specialists Lake Mary
Lake Mary, Florida, 32746, United States
-
SCRI-Florida Cancer Center Specialists Sarasota
Sarasota, Florida, 34236, United States
-
SCRI-Oncology Partners
Nashville, Tennessee, 37203, United States
-
SCRI-Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, 19107, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.